Navigation Links
Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
Date:1/10/2011

CAMBRIDGE, Mass. and NEW YORK, Jan. 10, 2011 /PRNewswire/ -- Resolvyx Pharmaceuticals (Resolvyx) and Celtic Therapeutics Holdings L.P. (Celtic Therapeutics), a successor firm to Celtic Pharma, announced today that they have entered into a final agreement under which Celtic Therapeutics has acquired and licensed worldwide rights related to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.  Terms of the deal include upfront consideration, near-term milestone payments, and funding for 100% of future development costs. Resolvyx and Celtic Therapeutics will share proceeds from the future divestiture of RX-10045, including up-front payments, royalties or other revenues.

Under the terms of the agreement, Celtic Therapeutics will acquire and license rights to Resolvyx's RX-10045, in all ophthalmic indications. RX-10045 is scheduled to enter a Phase III randomized, placebo-controlled, multi-center study in 2011. As part of the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx compound in a topical formulation for ophthalmic indications.

Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. Resolvins are shown to be highly potent and efficacious across a broad range of pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvyx will continue to develop Resolvins for non-ophthalmic indications.

Dry eye, one of the most common problems treated by ophthalmologists, and a $1.7 billion global market today, is a chronic, multifactorial disease involving inflammation of the tear ducts and ocular surfaces that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surfaces. RX-10045, a resolvin
'/>"/>

SOURCE Celtic Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... 21, 2014 CVS Caremark Corporation (NYSE: ... Yields and consideration payable in connection with its previously announced ... 2014 for (1) any and all of its 6.250% Senior ... up to a maximum amount of its 6.125% Senior Notes ... Notes due 2017 (collectively, the "Maximum Tender Offer Notes" and ...
(Date:8/21/2014)... 21, 2014 Professional Compounding Centers of ... by awarding the three best scientific presentations at ... conference . The Formulating Better Medicines for ... Athens, Greece , includes dozens ... professionals, from which three winners will be selected ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... THE WOODLANDS, Texas, Aug. 9, 2011 ... ), a biopharmaceutical company focused on discovering breakthrough ... data from its recently completed Phase 2 study ... etiprate. Carcinoid syndrome is a chronic condition caused ...
... SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 9, 2011 ... and Eisai Inc. announced today results from ... mammary tumor diagnoses from a two-year rat carcinogenicity study ... the lorcaserin Complete Response Letter (CRL), which questioned the ...
Cached Medicine Technology:Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 2Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 3Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 4Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 2Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 3Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 4Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 6
(Date:8/21/2014)... 21, 2014 The report "Industrial ... Pollutant Control System (FGD, DeNOx, Particulate Control, Mercury ... Steel, Chemical & Others) - Global Trends & ... industrial flue gas treatment systems & services market ... size in terms of value. The industrial flue ...
(Date:8/21/2014)... Revista, a one-stop source for ... data, is “on a roll.” Today, the Annapolis-based ... the Southeast, Mid-Atlantic and Midwest areas of the ... widely available, comprehensive medical property database tracking these ... properties, including existing and recently added, is 34,549. ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 ... dropped nearly 12 percent in the last decade, a new ... of teens using indoor tanning beds barely decreased. Both indoor ... skin cancers, including deadly melanomas, the researchers noted. "Unfortunately, ... who reported wearing sunscreen, from 67.7 percent in 2001 to ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... 2014 When children go back to school, ... cause them to become sick and risk missing school. It ... help them fight these germs to ensure a successful school ... just that with its XFactor program. , The XFactor program ... multi-vitamins. Children ages 4 and up can receive 30-day supplies ...
Breaking Medicine News(10 mins):Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:MedX Pharmacy Helps with Back to School Preparation 2
... Calif. - A single dose of antibiotics can significantly ... vaginal tissues during many births, according to researchers at ... School of Medicine and Santa Clara Valley Medical Center. ... simple treatment can prevent many of the short- and ...
... Mylan Inc. (NYSE: MYL ),today announced that ... U.S. Food and Drug Administration (FDA) for its,Abbreviated New ... 10,mg., Zaleplon Capsules are the generic version of ... $88 million for,the 12 months ending March 31, 2008, ...
... handful of measures are,effective, NEWTOWN, Conn., June ... and policy makers about the importance of choosing,the ... measurement,efforts, Bridges to Excellence(TM) (BTE) conducted a review ... physicians meet certain ambulatory,care quality measures. The study, ...
... Company donates $100,000 to American Red Cross, INDIANAPOLIS, ... arm of Eli Lilly and Company (NYSE: LLY ... assistance to aid,Indiana tornado and flood victims. More than ... Gov. Mitch Daniels as a result of deadly,tornadoes and ...
... Va., June 9 The National,Community Pharmacists ... Pharmacists (IACP) are collaborating to increase the,legislative ... in compounding.,IACP has established a satellite office ... Director of Public Affairs, Sarah R. Dodge. ...
... N.J., June 9 Wyeth (NYSE: WYE ... Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference on June ... Wyeth will be Bernard Poussot, President and Chief,Executive ... live for investors at, http://www.wyeth.com and available ...
Cached Medicine News:Health News:Antibiotics can prevent wound complications of childbirth, Stanford/Packard study finds 2Health News:Bridges to Excellence Study Assesses Clinical and Financial Impact of Physician Quality Measures 2Health News:Lilly to Provide Aid to Indiana Tornado and Flood Victims 2Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2
... plate acc. to Matzen is used for ... (HWS) with the exception of C0-C2. The ... fusion length until the bone transplant has ... the vertebral bodies, if possible along the ...
... The SC-Acufix anterior cervical plate system ... a patented, integrated swivel, which provides for ... and prevents bone screw disengagement or backout. ... a secondary locking screw. Simply implant your ...
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
... consisting of one part only, is made of ... compressed Polyamide may be rotated and moved as ... sizes and shapes, as well. Moreover they secure ... in caudal direction, which is one of the ...
Medicine Products: